Condition: Acute Myeloid Leukemia · Chronic Myeloid Leukemia · Acute Lymphoblastic Leukemia · Sponsor: University of Kansas Medical Center
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
This description comes directly from the study's public registry record.
Clinical Trial Nurse Navigator · 913-945-7552 · ctnursenav@kumc.edu
Always discuss trial participation with your own doctor first.
| University of Kansas Cancer Center | Westwood, Kansas, United States | Recruiting |
| Ohio State University Medical Center | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03533816